Abstract Psychostimulants are the recommended first-line pharmacological treatment for attention-deficit/hyperactivity disorder (ADHD). Methylphenidate is one of the most commonly used psychostimulants worldwide. Given that immediate-release and/or tablet/capsule formulations may decrease adherence to methylphenidate treatment, several drug companies have been developing novel long-acting and/or liquid/ chewable formulations that may improve adherence as well as (for long-acting formulations) reduce abuse potential, decrease stigma associated with multiple administrations per day, and decrease the potential for adverse effects related to dosage peak. Here, we review the pharmacokinetics, efficacy, and tolerability of novel formulations of methylphenidate that are in development or have been approved by the US FDA or European Medicines Agency (EMA) in the last 5 years. We searched the websites of the FDA, EMA, ClinicalTrials.gov, and the pertinent drug companies. We also searched PubMed, 
). Overall, available evidence based on trials suggests these compounds have good efficacy and tolerability. Future research should further explore the effectiveness and tolerability of these new formulations as well as their potential to improve adherence to treatment in the 'real world' via pragmatic trials.
Key Points
Swallowing methylphenidate tablets or capsules is challenging for some children with attention-deficit/ hyperactivity disorder.
Liquid and chewable formulations have been recently marketed or are in the late stages of clinical development.
Available evidence from trials shows these novel formulations have good efficacy and tolerability.
Introduction
Attention-deficit/hyperactivity disorder (ADHD) is one of the most common neuropsychiatric disorders [1] , with a pooled worldwide prevalence estimated at about 5% in school-aged children [1, 2] and impairing symptoms persisting into adulthood in up to 65% of cases [3] . According to the Diagnostic and Statistical Manual of Mental Disorders, fifth edition [4] , ADHD is characterized by ageinappropriate persistent and impairing levels of inattention and/or hyperactivity/impulsivity. ADHD is often comorbid with other psychiatric conditions, such as oppositional defiant disorder/conduct disorder, specific learning disorders, mood and anxiety disorders, substance use disorder, and sleep disturbances [5, 6] .
ADHD is a major public health issue [7] . Because of its core symptoms and associated disorders, ADHD imposes a huge burden on society in terms of psychological dysfunction, adverse personal outcomes, stress on families, and societal financial costs. For instance, average annual incremental costs of ADHD have been estimated at $US143-266 billion (year 2010 values) in the USA [8] .
Available treatments for ADHD include pharmacological and non-pharmacological interventions. Medications are indicated as the first-choice intervention in some guidance papers (e.g., the Practice Parameters of the American Academy of Child and Adolescent Psychiatry [9] ). Other guidance recommendations, such as those from the UK National Institute for Health and Care Excellence (NICE) [10] or the European ADHD Guidelines Group [11] , suggest that pharmacological treatment should be the first-line option for severe cases or should be considered for patients who have not responded to non-pharmacological interventions. Medications for ADHD include psychostimulants (i.e., methylphenidate and amphetamines), which are indicated as first pharmacological choice in some guidelines/recommendations (e.g., the NICE guidelines [10] ), and non-psychostimulant drugs (e.g., atomoxetine, clonidine, guanfacine) that may be considered as first option in patients with particular clinical profiles (e.g., comorbid substance use disorder) [12] . Methylphenidate is one of the most commonly used psychostimulants worldwide (see, for example, Pottegard et al. [13] , Brault and Lacourse [14] , and Hodgkins et al. [15] ). A large body of evidence, summarized in a number of meta-analyses of placebo-controlled double-blind randomized trials, shows the efficacy, at least in the short and medium term, and overall good acceptability/tolerability of psychostimulants, including methylphenidate, when used to control core ADHD symptoms in children, adolescents, or adults [16] [17] [18] [19] . Indeed, psychostimulants are one of the most efficacious drugs in psychiatry and more generally in medicine [20] . Despite their impressive performance in short-term trials, the optimization of effectiveness and long-term adherence in daily practice poses a major challenge to healthcare providers. For instance, findings from the initial randomized phase of the MTA (Multimodal Treatment for ADHD) study showed that community treatment, including medication not carefully titrated, was significantly less effective than carefully titrated and managed pharmacological treatment [21] . However, others have demonstrated that better outcomes are possible in routine care when this is well organized and delivered (e.g., Coghill and Seth [22] ).
A significant barrier to effective implementation of psychostimulants is treatment non-adherence, defined as the extent to which a patient's medication-taking behavior (timing, dosing, and frequency) does not correspond with recommendations from a healthcare provider [23] . Poor adherence to drugs is associated with a variety of factors, including patient characteristics, patient or caregiver choice, healthcare system-related factors, and medication-related factors [24] . The type of formulation may be a predictor of poor adherence, at least in a subset of patients with ADHD [24] . Two characteristics related to the formulation of methylphenidate may impact on adherence. First, short-acting formulations that must be taken several times a day may be impractical, children may be ashamed to take medication at school, or patients may simply forget to take multiple doses per day. In this respect, long-acting formulations of methylphenidate have been associated with significantly better adherence [24] . Second, most of the available preparations of methylphenidate are in the form of tablets or capsules, which may be a challenge for young patients who cannot swallow such formulations [25] . Although some formulations of methylphenidate may be opened and sprinkled over applesauce or suspended in water, this does not always allow for reliable delivery of a full dose of medication and may lead to incomplete delivery. Moreover, chewing the applesauce mixture may lead to dose dumping, defined as a condition in which the complete dose of a drug may be more rapidly released from the dosage form than intended [26] . Additionally, it is anecdotally reported that children often complain about the medication taste in the applesauce mixture [27] . While these issues might be overcome by available transdermal formulations, tolerability of these preparations may be a limiting factor [28] , tolerability of these preparations may be a limiting factor, especially given thedifferent pharmacokinetics of both L-and d-methylphenidate as they bothcircumvent hepatic first-pass metabolism. Therefore, several drug companies have been developing long-acting formulations that may overcome these challenges.
The aim of this paper is to provide a review of the methylphenidate formulations under development or approved in the last 5 years, focusing on their pharmacokinetics, efficacy, and tolerability profiles. Although this is not a formal systematic review with an appraisal of the level/quality of evidence, we endeavored to conduct a comprehensive search of peer-reviewed published and unpublished material. With regards to drugs approved in the last 5 years, since approval may change from country to country and clearly it would be unfeasible to cover all countries around the world, we restricted the search to the websites of two major regulatory bodies: the US FDA [29] and the European Medicines Agency (EMA) [30] . We also searched the websites of relevant drug companies (identified via ClinicalTrials.gov [31] [31] for studies on any of the above-mentioned compounds in ADHD, restricting the search to completed studies with available results.
In the following sections, we present the pharmacokinetics, efficacy, and tolerability of each compound based on data from the above-mentioned sources. Available data are summarized in Table 2 . We note that the percentage of immediate-release (IR) and XR product varies across the formulations reviewed in this paper. .31 ng h/ml, respectively, under fasting conditions. The mean peak plasma concentration (C max ) was 13.61 ng/ml for MEROS and 20.94 ng/ml for MPH IR. The half-life of MEROS was 5.65 h, and the time at which the C max was observed (t max ) was 5 h, whereas the half-life of MPH IR was 3.74 h, and the t max was 7.33 h. Therefore, while the AUC 0-? with a single dose of MEROS 60 mg in fasting subjects was bioequivalent to two 30-mg doses of MPH IR, the C max was about 35% higher for MPH IR than for MEROS. Although there was no significant difference in rates of side effects between the two compounds (the most common adverse effects [AEs] being headache, dizziness, palpitations, nausea, and nervousness), the two different profiles mean that making any direct comparison of dose-related AEs is challenging. The t max for MEROS was 4 h in the fed state and 5.2 h in the fasted state. The rate and extent of exposure to d-methylphenidate was *25% higher when MEROS was administered under fed conditions than under fasted conditions, which suggests a high-fat meal may increase the bioavailability and decrease the t max of MEROS.
Children/Adolescents
Data on the pharmacokinetics of MEROS in children and adolescents were obtained in an open-label single-dose study that enrolled 14 youths (seven children aged 9-12 years and seven adolescents aged 13-15 years). Participants received a single dose of MEROS (20 or 60 mg), after which they were encouraged to eat and drink [32] . Samples were collected at pre-dose and at 0.5, 1, 2, 4, 6, 8, and 12 h post-dose on day 1 and at 24 h post-dose on day 2. Mean C max generally occurred between 2 and 4 h after the dose. After the 20-mg dose, the mean C max , t max , and AUC 0-? were 11.5 ng/ml, 2.99 h, and 101 ng h/ml in children and 9.22 ng/ml, 2.00 h, and 82.4 ng h/ml in adolescents, respectively. After the 60-mg dose, the mean C max , t max , and AUC 0-? were 34.4 ng/ ml, 4.05 h, and 378 ng h/ml in children and 21.1 ng/ml, 2.00 h, and 178 ng h/ml in adolescents, respectively. Thus, mean drug concentrations were similar for the children and adolescent age groups after a 20-mg dose, whereas higher concentrations were observed for children than for adolescents after a 60-mg dose. However, these differences in plasma concentrations between children and adolescents appear to be accounted for by body weight differences, since mean weight-adjusted C max and AUC values were similar between children and adolescents.
Based on these data and on indications in the FDA Summary of Product Characteristics [33] , we highlight the following clinically relevant implications: -The pharmacokinetics of MEROS after oral administration is linear and proportional to dose. -Onset of effect occurs at 45 min and lasts through 12 h after dosing. -The relative bioavailability of MEROS 60 mg compared with MPH IR 60 mg oral solution (given as two 30-mg doses 6 h apart) is 95%. -A high-fat meal may increase the bioavailability of MEROS. -The recommended starting dose is 20 mg, and dose may be increased weekly by 10-20 mg increments. Doses above 60 mg daily have not been studied and are not recommended. -Because of its half-life (*5.7 h) and once-daily dosing regimen, the pharmacokinetics of MEROS are not expected to change after multiple-dose administration compared with single-dose administration (methylphenidate demonstrates time-independent linear pharmacokinetics). The first dose is almost completely eliminated at the end of a 24-h period, and no significant accumulation of methylphenidate would be expected. -There is no noticeable relationship between body weight and final dose. Therefore, weight-based dosing is not necessary. -The small increase in exposure compared with IR products is not expected to have a large effect on the efficacy or safety of the product.
Efficacy
We retrieved two published publications [34, 35] and partial results in a conference proceedings abstract [36] on one trial providing data on the short-term efficacy of MEROS (NCT00904670). The trial was a dose-optimized, randomized, double-blind, placebo-controlled, crossover laboratory school study that enrolled 45 children with ADHD (aged 6-12 years). After an open-label phase aimed to optimize the dose, participants received 2 weeks of double-blind treatment (1 week each of MEROS and of placebo), with treatment sequence (MEROS/placebo or placebo/MEROS) randomly assigned. The primary efficacy outcome was the SKAMP (Swanson, Kotkin, Agler, M-Flynn, and Pelham) [37] combined score at 4 h postdose. Additional secondary efficacy outcomes included the four SKAMP subscales (SKAMP-Attention, SKAMP-Deportment, SKAMP-Quality of Work, and SKAMP-Compliance) and the PERMP (Permanent Product Measure of Performance) mathematics tests [38] . The ADHD-Rating Scale (ADHD-RS) [39] and the Clinical Global Impression-Severity (CGI-S) as well as CGI-Improvement (CGI-I) scales [40] were used in the open-label phase. Considering data in the completers (n = 39), at endpoint, mean scores of the SKAMP combined scale in the MEROS arm (7.12) were significantly decreased compared with those in the placebo arm (19.58). MEROS was also significantly more efficacious than placebo when considering the subscales of the SKAMP and the PERMP. During the openlabel phase, the scores for the ADHD-RS, CGI-S, and CGI-I scales improved.
Tolerability
Overall, data on the tolerability of MEROS are consistent with known AEs during treatment with methylphenidate. In the above-mentioned randomized controlled trial [34, 35] 
Efficacy
We did not find any study published in a peer-reviewed journal on the efficacy of MPH ERCT in individuals with ADHD. However, we retrieved the results of a study reported as ''completed'' in ClinicalTrials.gov (NCT01654250) [42] . This was a multicenter, dose-optimized, double-blind, randomized, placebo-controlled study in children aged 6-12 years. Of the 90 subjects enrolled in the study, 86 were randomized to MPH ERCT or placebo for 1 week after an open-label dose-optimization phase (1-6 weeks). The primary outcome was the SKAMP [37] combined score. Secondary outcome measures included onset and duration of clinical effect, SKAMP-Attention and -Deportment subscale scores, and PERMP scores. Other outcome measures included CGI-S, CGI-I, and Conners Parent Rating Scale scores. Available results for the primary outcome and secondary outcomes (except for the CGI values, for which results were not provided), showed that MPH ERCT was statistically superior to placebo (primary outcome: SKAMP combined score, p \ 0.001; secondary outcomes: onset and duration of clinical effects: p \ 0.001; SKAMP-Attention and -Deportment subscales scores: p = 0.007; PERMP: p = 0.024) [42] .
Tolerability
In the above-mentioned randomized controlled trial, no serious events were reported with MPH ERCT or with placebo. A total of 31 non-serious AEs were recorded for MPH ERCT and 33 for placebo. The most common AEs with MPH ERCT were decreased appetite; insomnia, headache; abdominal pain; and upper respiratory tract infections. No analyses were reported to test whether any of the AEs was significantly more frequent in the placebo arm or the MPH ERCT arm.
In the pharmacokinetics study [41] , the 21 AEs reported with MPH ERCT and the 17 reported with MPH imemdiaterelease chewable tablets (MPH-IRCT). Of these, 10 and 13 were considered related to MPH ERCT and MPH-IRCT, respectively, including hypertension (MPH ERCT = 2 subjects, MPH IRCT = 2), dizziness (MPH ERCT MPH ER capsules comprise approximately 40% IR and 60% controlled-release layers of methylphenidate. The controlled-release layers comprise a coating that provides controlled release of the drug substance.
Pharmacokinetics

Adults
The pharmacokinetics of MPH-MLR in adults has been reported in two studies. The first [43] was a single-center, randomized, open-label, single-dose, three-period crossover study that evaluated the relative bioavailability of three doses (4 h apart) of MPH IR 25 mg and a single dose of MPH-MLR 80 mg as capsule and sprinkles (the powder from within the capsule), both received in the fasted state. Serial blood samples were obtained (with intervals ranging from 30 min to 4 h) before dosing (B15 min) and up to 24 h post-dose for 4 days. Mean C max , t max , and AUC 0-? were 23.5 ng/ml, 2.0 h, and 258.1 ng h/ml for the MPH-MLR capsule, 21.8 ng/ml, 2.0 h, and 258 ng h/ml for MPH-MLR sprinkles, and 29.1 ng/ml, 9.5 h, and 281.7 ng h/ml for MPH IR, respectively. The plasma concentrations of MPH-MLR capsule and sprinkles, which were bioequivalent, were characterized by a rapid initial peak, followed by a moderate decline until 5 h post-dose, and a gradual increase until 7 h post-dose, up to a second attenuated peak. Additionally, total systemic exposure over the first 4 h post-dose with MPH-MLR (as capsule or sprinkles) was significantly higher than that associated with the first dose of MPH IR.
The second study [44] was a single-center, randomized, open-label, single-and multiple-dose, two-period crossover study that assessed the relative bioavailability of three doses (4 h apart) of IR MPH 25 mg daily and a single daily dose of MPH-MLR 80 mg under fed conditions (multi-dose study) in 42 subjects (21 each randomized to MPH IR or MPH-MLR). The profile of MPH-MLR 80 mg was characterized by a rapid initial peak, followed by a moderate decline reaching a plateau about 5 h post-dose, followed by an increase up to an attenuated second peak about 7 h post-dose. Serial blood samples were collected just before dosing (B15 min) and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 4.5, 5, 5.5, 6, 6.5, 7, 8, 8.5, 9, 9.5, 10, 10.5, 12, 15, 19, and 24 h post-dose. Assessments were performed on day 1 after a high-fat breakfast and on day 4 in the fed state after a standard meal. On day 1, mean C max , t max , and AUC 0-? were 23.7 ng/ml, 3.0 h, and 289.9 ng h/ml for MPH-MLR and 31.5 ng/ml, 9.0 h, and 294.5 ng h/ml for MPH IR, respectively. At steady state (day 4), mean C max , t max , and AUC 0-? were 28.1 ng/ ml, 2.0 h, and 305.4 ng h/ml for MPH-MLR and 32.9 ng/ml, 6.0 h, and 323.9 ng h/ml for MPH IR, respectively. Thus, a MPH-MLR 80-mg capsule taken once daily provides maximum methylphenidate concentrations comparable to MPH IR 25 mg taken three times daily.
Children/Adolescents
A single-center, randomized, open-label, two-way cross-over study comparing MPH-MLR (10, 15, 20, 30 , and 40 mg strengths) and MPH IR (10 and 20 mg strengths) provided pharmacokinetic data in children aged 6-12 years [45] . Plasma samples were obtained pre-dosing and 1, 2, 3, 4, 5, 6, 8, 10, 12, and 24 h post-dose. In total, 14 participants completed the randomization, separated by a 14-day wash-out period. Mean C max , t max , and AUC 0-? were 12.12 ng/ml, 3.97 h, and 155.11 ng h/ml for MPH-MLR and 20.41 ng/ml, 5.47 h, and 144.95 ng h/ml for MPH IR, respectively. The study highlighted that the pharmacokinetics of MPH-MLR are similar in children and adults and that MPH-MLR is similarly bioavailable to an equivalent dose of MPH IR administered twice daily, avoiding the peaks associated with the latter.
Based on the reviewed data and indications in the FDA Summary of Product Characteristics [33] , we highlight the following clinically relevant implications:
-MPH-MLR produced a better fluctuation index (less variability) than MPH IR. -Pharmacokinetic profiles in pediatric patients are associated with large variability. The large inter-subject variability in pharmacokinetic profiles supports a titration-based dosing regimen to achieve an optimal treatment effect for each individuals.
-A starting dose of 10 mg with incremental 10-mg increases every week is recommended. -MPH-MLR can be given without regard to meals. -About 80% of the drug is released within 1 h in 40% alcohol. Patients should be advised to avoid alcohol while taking MPH-MLR. -Similar mean efficacy and safety profiles are expected when MPH-MLR is given as a whole capsule or sprinkled into applesauce.
Efficacy
The efficacy of MPH-MLR was evaluated in two studies. In the first [46] , a parallel, double-blind, multicenter, placebo-controlled, forced-dose, phase III study, 221 participants with ADHD (aged 6-18 years) were randomized to placebo or MPH-MLR 10, 15, 20, or 40 mg once daily for 1 week followed by an 11-week open-label dose-optimization period. The primary efficacy analysis showed the mean decrease in the ADHD-RS-IV [47] from baseline to the end of the double-blind phase differed significantly among study arms. Additionally, ADHD-RS-IV total scores in subjects randomized to the 20-mg (p = 0.0145) and 40-mg (p = 0.0011) arms, but not in those assigned to the 10-mg (p = 0.2083) or 15-mg (p = 0.0769) arms, were significantly decreased compared with those from subjects in the placebo arm. ADHD-RS-IV total scores decreased during the open-label phase, with a total decrease of 22.5 points from baseline. The second study [48] was a randomized double-blind placebo-controlled trial including an open-label dose-optimization treatment period (2-4 weeks) in a laboratory school setting followed by a double-blind crossover period in which 20 children with ADHD (aged 6-12 years) were randomized to a sequence of either 1 week of placebo or optimized MPH-MLR or vice versa. Results showed that the least-squares mean post-dose SKAMP total score was significantly lower (p = 0.0001) for children who received MPH-MLR than for those receiving placebo. Effects were observed within 1.0 h and up to 12.0 h post-dose.
Tolerability
In the above-mentioned study [46] , two serious AEs were reported (one participant receiving MPH-MLR 15 mg was hospitalized for ''adjustment disorder with mixed disturbance of emotion and conduct'', and another participant receiving MPH-MLR 30 mg was diagnosed with injury-related migraine headache); both were considered not related to study medication. Two patients receiving MPH-MLR 40 mg reported insomnia, and one participant receiving MPH-MLR 10 mg was reported with crying, both considered severe AEs. In the open-label phase, two severe AEs were considered related to study treatment (aggression and mood swings) and two severe AEs were considered not related to study treatment (viral gastroenteritis and viral infection). The other most common AEs during the openlabel phase were decreased appetite (19.0%), headache (17.6%), insomnia (11.8%), upper abdominal pain (10.9%), upper respiratory tract infection (6.3%), irritability (5.4%), and fatigue (5%). In the other published study [48] on the efficacy/tolerability of MPH-MLR, the most common treatment-related AEs in the open-label or double-blind phases included decreased appetite, headache, irritability, cough, nasal congestion, rhinorrhea, pyrexia, otitis media, abdominal pain, vomiting, and insomnia, all classified as mild or moderate. No serious AEs were reported.
Methylphenidate XR Orally Disintegrating
Tablets (MPH XR-ODT; NT-0102, Cotempla TM )
This is an orally disintegrating tablet methylphenidate formulation. We could retrieve only two studies, both presented as posters and, to our knowledge, not yet published as peerreviewed full reports. The first study [49] was a single-dose, open-label, single-period, single-treatment phase I study aimed at assessing pharmacokinetics in a sample of 32 children and adolescents with ADHD. Mean estimates of oral clearance (CL/F) increased with age, although weightnormalized CL/F values were comparable across age groups. Additionally, mean estimates of Apparent volume of distribution during terminal phase after oral/extravascular administration (V z /F) increased with age, but weight-normalization decreased differences across age groups, although the youngest age group had higher values. The second study [50] was a multicenter, double-blind, placebo-controlled, parallel-group trial in which 87 children with ADHD were randomized to MPH XR-ODT or placebo. Study treatment was significantly superior to placebo on the primary study outcome (SKAMP combined score, p \ 0.0001). Effects were evident up to 12 h post-dose. The most common treatment-emergent AEs during the study were decreased appetite, upper abdominal pain, headache, insomnia, upper respiratory tract infection, affect lability, irritability, cough, and vomiting. Most AEs were rated as mild. 
Conclusions and Future Perspectives
New long-acting formulations of methylphenidate have recently been developed or are currently under development with the aim of overcoming the challenges in swallowing tablets/capsules, which may be a real issue for a subgroup of children with ADHD, ensuring optimal therapeutic benefit during the day, decreasing stigma associated with multiple administrations per day, and decreasing the potential for abuse and adverse effects related to dosage peak. Evidence from a still limited number of randomized trials supports the efficacy, in the short term, and overall good tolerability of the FDA-approved formulations described in our paper. In our view, this initial body of research sets the groundwork for future investigations aiming to assess the effectiveness and tolerability of these new formulations in the 'real world'. In this regard, pragmatic trials would be particularly welcome. Such trials should include participants who are selected based on clinical presentation rather than on strict categorical definition, should use outcomes meaningful for day-to-day clinical practice, and should aim to assess the possible superior palatability and tolerability of the new compounds over available drugs [52] .
It would be particularly worthwhile to test efficacy/effectiveness and tolerability of these new formulations, such as liquid or chewable methylphenidate, in populations of children with ADHD for whom swallowing oral tablets/capsules is a particular challenge, such as those with comorbid autism spectrum disorder (ASD) or preschoolers, since clinical experience of the authors suggests that opening available formulations and sprinkling the contents on food or dissolving it in water is not always feasible with these specific clinical subgroups. In fact, trials with novel formulations of methylphenidate are ongoing in individuals with ADHD and ASD (e.g., NCT02096952). Finally, the real potential of these new formulations would be tested in studies assessing the extent to which they improve medication adherence in 'real-world' settings. To date, these novel formulations are still niche products and do not seem to have substantially impacted daily prescription practices. Given their recent introduction to the market and their availability in a limited number of countries, it is premature to assess their real impact in daily clinical practice. Future studies, particularly pragmatic trials, may have the potential to provide empirical support to the claimed added value of these new formulations. Additional clinical studies may provide further information regarding the pattern of efficacy across the day according to the different pharmacokinetics and methylphenidate delivery profiles of each formulation. Variability in pharmacokinetic profiles has been reported in long-acting methylphenidate medications across the day at an individual level [53] . This issue may be explored in these new formulations may and indicate possible specific dosing strategies or switching from one to another formulation to optimize individual response. Pragmatic head-to-head studies of alternative combinations of long-acting formulations are the best evidence-based guidance for a tailored treatment approach. Furthermore, pharmacovigilance studies will be pivotal in the full assessment of their safety and tolerability profile. Finally, studies exploring patients' preferences will be informative and help clinicians understand the extent to which the favorable profile of these formulations, highlighted in the studies reviewed in this paper, translates in the real world.
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